Market Size (2015)
2015
$56.53B
Healthcare
Duloxetine Intermediate Atorvastatin Intermediates Market
By Segment, By Region, And Segment Forecasts, 2015 – 2023
Vertical: HealthcareBase Year: 201718 Sections
Executive Summary
Duloxetine Intermediate Atorvastatin Intermediates Market — Snapshot
Projected (2023)
2023
$73.55B
CAGR (2015–2023)
3.3%
3.3%Key Players
107+
The duloxetine is type of antidepressant known as serotonin norepinephrine reuptake inhibitor used to treat depression and anxiety and also widely approved for the treatment of stress urinary incontinence in women and other chronic diseases. The atorvastatin is commonly used in lowering the cholesterol level and helps prevent cardiovascular diseases. Increasing aging patient population, the rising incidences of chronic diseases globally, and increasing disease awareness drive the growth of the global duloxetine intermediate and atorvastatin intermediates market. However, stringent regulatory policies may hamper the growth of the market.
The global duloxetine intermediate and atorvastatin intermediates market is expected to register a CAGR of 4.04% during the forecast period from 2018 to 2023. In 2017, the market was led by the Americas with 35.7% share, followed by Europe and Asia-Pacific with shares of 31.5% and 25.2% respectively.
The global duloxetine intermediate and atorvastatin intermediates market have been segmented based on intermediate type and region.
Based on intermediate type, the duloxetine intermediate segment accounted for the largest market share of 54.9% in 2017, with a market value of USD 32,393.03 thousands, which is projected to register a CAGR of 4.25% during the forecast period
Key Insight
The Duloxetine Intermediate Atorvastatin Intermediates Market market is projected to grow at a CAGR of 3.3% from 2015 to 2023.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 5 regions: Middle East and Africa, North America, Asia Pacific, Europe, South America.
- Market Segmentation: The market is analyzed across key segments with forecasts from 2015 to 2023.
- Competitive Landscape: 107 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Duloxetine Intermediate Atorvastatin Intermediates Market — Growth Trajectory
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) which is widely approved for the treatment of stress urinary incontinence in women, major depressive disorder (MDD), and other chronic diseases. It reduces painful physical symptoms in depressed patients. Hence these are also recommended in the treatment of diabetic peripheral neuropathic pain (DPNP). As there is a rising prevalence of the major depressive disorder among adults, the demand for duloxetine intermediate is increasing.
The atorvastatin is commonly used in lowering the cholesterol level and helps prevent cardiovascular diseases. Hence it helps to boost the growth of the global duloxetine intermediate and atorvastatin intermediates market.
Market Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Intermediate Type Intermediate Type is broken down into: Duloxetine Intermediate ((S)-(-)-N,N-Dimethyl-3-hydroxy-3-(2-thienyl)propanamine (CAS No. 132335-44-5)), Atorvastatin Intermediates.
Geographic Analysis
Regional market breakdown
- Middle East and Africa Middle East and Africa market size reached $4.30B in 2015 and is projected to reach $5.62B by 2023, growing at a CAGR of 3.4%.
- North America North America market size reached $17.78B in 2015 and is projected to reach $22.24B by 2023, growing at a CAGR of 2.8%.
- Asia Pacific Asia Pacific market size reached $14.02B in 2015 and is projected to reach $19.46B by 2023, growing at a CAGR of 4.2%.
- Europe Europe market size reached $17.75B in 2015 and is projected to reach $23.28B by 2023, growing at a CAGR of 3.4%.
- South America South America market size reached $2.68B in 2015 and is projected to reach $2.95B by 2023, growing at a CAGR of 1.2%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Duloxetine Intermediate Atorvastatin Intermediates Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Research Process
Historical data (2015–2017) and forecast period (2017–2023)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Duloxetine Intermediate Atorvastatin Intermediates Market — Competitive Analysis
Threat of New Entrants
The threat of new entrants in the global duloxetine intermediate and atorvastatin intermediates market is moderate to high. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. The market has a high threat of new entrants, threatening the existing players. Moreover, the cost involved in R&D is comparatively high which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global duloxetine intermediate and atorvastatin intermediates market is medium. The suppliers in the global duloxetine intermediate & atorvastatin intermediates industry are the manufacturers of chemical compounds of duloxetine and atorvastatin. Currently, a moderate number of suppliers are present in the market due to stringent government regulations and high opportunities. Currently, major players are accounting for a significant share of the market. Switching cost of the suppliers is medium because suppliers tend to enter into long-term associations, partnership, and deals with the companies that sell duloxetine intermediate & atorvastatin intermediates.
Threat of Substitutes
The threat of substitutes in the global duloxetine intermediate and atorvastatin intermediates market is high. Currently, duloxetine intermediate & atorvastatin intermediates have many direct substitutes. For instance, duloxetine has substitutes like venlafaxine, citalopram, fluvoxamine, etc. Also, atorvastatin has substitutes like lovastatin, rosuvastatin, simvastatin, etc. Hence, the threat of substitutes is high in the duloxetine intermediate and atorvastatin intermediates market, due to the availability of many options in the market.
Bargaining Power of Buyers
Buyers of duloxetine intermediate and atorvastatin intermediates are the manufacturers of duloxetine and atorvastatin APIs. The bargaining power of the buyers is medium in the global duloxetine intermediate and atorvastatin intermediates market due to the presence of a moderate number of providers of duloxetine intermediate & atorvastatin intermediates. Also, buyers prefer products manufactured by known brands. However, there are many big brands present in the market. Because of this, the bargaining power of the buyers is medium.
Intense Rivalry
The degree of competition in the global duloxetine intermediate and atorvastatin intermediates market is high. Many companies are present in this market. These players have a moderate degree of product differentiation. They are introducing innovative and more affordable products in the market. These factors increase the rivalry in the duloxetine intermediate and atorvastatin intermediates market. Companies involved in the market are trying to acquire new players in the market and merge with major players to survive in the market. Big brands are trying to acquire small players of the market, to create a competitive edge, which is creating a high level of rivalry in the market.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Duloxetine Intermediate Atorvastatin Intermediates Market.
Regional Market Size (USD Mn)
Market estimates by geography (2023)
USD Mn
InsightEurope leads with $23.28B by 2023, while Asia Pacific is projected to grow fastest at a 4.2% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $4.30B | $4.74B | $5.62B | 3.4% | 8% |
| North America | $17.78B | $19.22B | $22.24B | 2.8% | 30% |
| Asia Pacific | $14.02B | $15.95B | $19.46B | 4.2% | 26% |
| Europe | $17.75B | $19.63B | $23.28B | 3.4% | 32% |
| South America | $2.68B | $2.73B | $2.95B | 1.2% | 4% |
| Total | $56.53B | $62.27B | $73.55B | 3.3% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Duloxetine Intermediate Atorvastatin Intermediates Market — Key Findings
Analytical insights on Duloxetine Intermediate Atorvastatin Intermediates Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Duloxetine Intermediate Atorvastatin Intermediates Market market is projected to reach $73.55B by 2023, growing at 3.3% CAGR.
Market Dynamics
Duloxetine is an orally administered antidepressant drug that is used for the treatment of the major depressive disorder (MDD). The pre-clinical trials of duloxetine have proved that it is significantly more efficacious in the treatment of major depressive disorders. It is the most widely preferred drug for the treatment of MDD and drug interaction with the body is less as compared to other serotonin reuptake inhibitors (SNRI). It is also used in the treatment of multiple sclerosis, chronic pain conditions, and in painful diabetic neuropathy. As per a survey carried out by the US National Library of Medicines in 2015, around 3,50,000 to 4,00,000 Americans had multiple sclerosis, and duloxetine intermediates were used for the treatment. Duloxetine was first approved in 2004 for the treatment of various chronic disorders such as major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), fibromyalgia, and chronic musculoskeletal pain. It was also used for the treatment of GAD in pediatric patients aged 7 to 17 years.
Atorvastatin is used to lower the bad cholesterol and fats and helps to raise good cholesterol in the blood. It is a salable cholesterol-lowering drug with worldwide annual sales exceeding 10 billion dollars in 2017. Multiple prospective studies have shown the cardioprotective and antioxidant effects of atorvastatin intermediates which had been used widely from many decades. LDL-cholesterol levels remain the principal target for lipid modification and hence the atorvastatin therapy is most widely used to lower the cholesterol level. Atorvastatin therapy is associated with a significant reduction in cardiovascular endpoints. However, concerns have been raised over the use of atorvastatin and an increased risk of diabetes. However, factors such as the rising prevalence of MDD, rising incidence of chronic diseases, and increasing demand for atorvastatin intermediates may hamper the growth of the market during the forecast period
Market Drivers
Depression is a mood disorder that causes loss of interest and a persistent feeling of sadness. It is also known as major depressive disorder. It leads to various emotional and physical problems. It is a major public health problem worldwide and a leading cause of disability as well as mortality along with socioeconomic problems. It affects a large number of people including both men and women. Globally major depressive disorder (MDD) is the most prevalent mental disorder. As per a survey carried out by the National Institute of Mental Health in 2016, 16.2 million adults in the US had at least one major depressive disorder. The prevalence was found higher among adult females that are 8.5% as compared to males that are 4.8%. A major depressive disorder is one of the leading causes of disability worldwide and is a major contributor to the overall global burden of diseases in low- and middle-income countries. As per the Global Health Estimate Report 2015, the global proportion of the population with depression was estimated to be 4.4%. It is more common in females of the 55 to 74 year age group. Hence, the prevalence of depression is growing every year.
Market Opportunities
Developing economies pose an opportunity for various markets as they have undeveloped research and development sectors owing to which they are unable to address upcoming health challenges. Despite huge demand, the African region is dependent on imported medicines and other health technologies. Although there is a high requirement for treatment, poor economic conditions lead to the slow growth of the healthcare industry within the African region. As per the statistics report of the World Health Organization (WHO) 2017, around 80% of the population affected with chronic disease lived in low- and middle-income countries. This huge population affected with the chronic disease in developing countries serves as a strong opportunity for key players operating in the global duloxetine intermediate and atorvastatin intermediates market. The increasing prevalence of various chronic diseases has served a good platform for manufacturers. Many types of active pharmaceutical ingredients are available in the market. However, many of them have different side-effects, and thus, there are a number of opportunities for manufacturers to develop new drugs. Many drugs are not prescribed to patients suffering from hypernatremia and other chronic diseases. Besides this, there are huge opportunities for the development of the market in developing countries. Thus, the development of new drugs can pose lots of opportunities for the growth of the market
Market Restraints
In 2017 the US health care cost was USD 3.5 trillion. Hence the US is one of the leading countries in the healthcare sector. The rise in healthcare cost can be observed due to the increasing prevalence of chronic diseases such as diabetes and heart diseases. These are responsible for 85% of the total healthcare costs. Almost half of the American population is suffering from either one of the chronic diseases. As there is a growing prevalence of chronic diseases the demand for atorvastatin intermediate is also increasing. The second cause of rising health care cost is widespread in preventable diseases. The leading causes of death are due to heart disease, cancer, chronic obstructive pulmonary disorder, and stroke. These diseases can be prevented if diagnosed at an early stage. Smoking is an important cause of lung cancer and chronic obstructive pulmonary disease (COPD). These diseases cost around USD 7,900 per person which is five times more than the health care cost for a healthy person. The average cost of treating diabetes is USD 26,971 per family. These diseases are difficult to manage because patients get tired of taking numerous medications. Hence rise in healthcare cost can be observed in recent years
Strategic Outlook and Future Directions
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Companies
Key companies profiled in Duloxetine Intermediate Atorvastatin Intermediates Market
Profiles of 107 companies operating in the Duloxetine Intermediate Atorvastatin Intermediates Market market, including revenue, employee count, and market positioning where available.
Showing 107 of 107 companies
Chiral Bio
Chiral Bio Sciences Ltd
Healthcare
Company Headquarters: India Founded: 2008 Company Working: Chiral Bio Sciences Ltd (Chiral) is one of the fastest growing companies in the area of synthetic technology and chiral compounds. The company harnesses a combination of extensive expertise and latest technology and offers quality products and solutions that are innovative and cost-effective, catering to the rigorous and wide-ranging requirements of customers in the industry. Chiral embodies the vision of a top-notch player in developing and commercializing products catering to a variety of therapeutic categories. It currently manufactures advanced drug intermediates for Anti Retro Virals, Anti-Hypertensive, Anti Diabetic, etc. Chiral presently has an R&D Center with attached pilot plant and two commercial production units, totaling 80 KL capacity. It follows and maintains good manufacturing practices. A state-of-the-art manufacturing unit consisting of two production blocks of 80 KL each, meets all the international regulatory requirements that have been set up. The R&D Center is also scaled up to high levels/standards
RevenueN/A
EmployeesN/A
Market CapN/A
Founded2007
India
Fluorochem
Fluorochem Ltd
Healthcare
Company Headquarters: United Kingdom Founded: 1999 Workforce: 50+ Company Working: Fluorochem Ltd has been supplying intermediates for research and development to pharmaceutical companies, universities, biotechnology companies, and contract research organizations for over 40 years. The product portfolio of nearly 100,000 items includes organic research intermediates, fluorinated products, heterocyclic, boronic acids, Sulphur compounds, novel organics, organometallics, silanes, siloxanes, biochemicals, NMR solvents, NMR tubes, silica gel for chromatography, and thin layer chromatography (TLC) plates. In 2010 the company completed a three-year project to move the whole company into a brand new, purpose designed facility in Hadfield. This has enabled it to streamline its processes, store the chemicals more effectively, and improve and enhance QC facilities. Furthermore, the company has got an opportunity to review its procedures fundamentally and amongst other improvements, it has developed its material safety data sheet (MSDS) and labeling software to comply with Globally Harmonized System (GHS)/ Classification, Labeling and Packaging (CLP) regulations, and created a new internal system for order handling and stock maintenance. It has nearly 20000 products in stock for immediate delivery, some in bulk quantities. Moreover, many of its products can be produced in multi-kg quantities at the company’s US sister company, Oakwood.
RevenueN/A
Employees50
Market CapN/A
Founded1998
United Kingdom
Shodhana L
Shodhana Laboratories
Healthcare
Company Headquarters: India Founded: 2000 Workforce: 1,000+ Company Working: Shodhana Laboratories is a WHO GMP ISO 9001-2008 and ISO 14000:2004 certified company. It is considered to be one of the most dynamic active pharmaceutical ingredients and intermediates manufacturing companies. Its facility has been audited and approved by the Korea Food and Drug Administration (KFDA), Federal Committee for Protection from Sanitary Risks (COFEPRIS) (Mexico), and Therapeutic Goods Administration (TGA) (Australia). The company has the most technically advanced production facilities, and its entire manufacturing process is as per the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) & Current Good Manufacturing Practices (cGMP) guidelines. Shodhana Laboratories also has a world-class R&D lab manned by a dynamic team of highly qualified and experienced scientists
RevenueN/A
Employees1,000
Market CapN/A
Founded1999
India
Afine Chem
Afine Chemicals Ltd
Healthcare
Company Headquarters: China Founded: 2005 Company Working: Afine Chemicals Ltd (Afine) specializes in fine chemicals and pharmaceuticals. Its products have earned great popularity in world markets. Since 2005, the company had been rapidly growing to become a leading manufacturer and trader of APIs in China. Afine has set up two independent business divisions, namely, fine chemicals division and pharmaceutical division. Afine’s chemical department is involved in manufacturing and trading of a variety of high-quality optical brightener and textile auxiliary as well as dyestuff, pigments, and other fine chemicals. The company is one of the leading exporters of optical brightener in China. The pharmaceutical division is involved in manufacturing, contract R&D, marketing and distribution of active pharmaceutical ingredients, intermediates, and feed additives. In March 2009, the Hangzhou government awarded “Top 100 innovation-oriented export enterprises of Hangzhou in 2008” among more than 13,000 export enterprise of Hangzhou
RevenueN/A
EmployeesN/A
Market CapN/A
Founded2004
China
Arch Pharm
Arch Pharmalabs
Healthcare
Company Headquarters: India Founded: 1999 Workforce: 5,000+ Company Working: Arch Pharmalabs is a world-class provider of small molecule process chemistry, custom synthesis services, and full life-cycle API and drug intermediates manufacturer for the global pharmaceutical industry. It has generated revenues of USD 200 million. Its India-based offering is supported by 2,400 customer-centric employees, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites), and two state-of-the-art process technology centers. Arch Pharmalabs works tirelessly to deliver value, innovation, and effective supply chain solutions in the spirit of true partnership. Its large family of satisfied customers ranges from emerging or specialty companies to global majors, many of whom have designated Arch Pharmalabs as a preferred supplier or strategic partner. Arch Pharmalabs received CNBC TV Emerging India 2006 Award as the No.1 Small or Medium Company in the Pharmaceuticals and Chemicals category
RevenueN/A
Employees5,000
Market CapN/A
Founded1998
India
Manus Aktt
Manus Aktteva
Healthcare
Company Headquarters: India Founded: 1997 Workforce: 10+ Company Working: Manus Aktteva is an ISO 9001:2008 certified organization. It is a well-informed, highly efficient, swiftly functioning competitive sourcing entity. It serves private, institutional, and corporate clients worldwide in the field of pharmaceuticals and nutraceuticals. It combines its contacts, expertise, and core competency with its operations to deliver superior pharmaceutical sourcing solutions to customers. It has its base in India and has been serving clients in more than 50 countries. It specializes in global sourcing in the field of pharmaceuticals and nutraceuticals, facilitation of new molecule research, documentation support, i.e., Chemistry, Manufacturing & Controls (CMC) data package, and scale up new intermediates, exports, and imports
RevenueN/A
Employees10
Market CapN/A
Founded1996
India
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Duloxetine Intermediate Atorvastatin Intermediates Market
Starting from
$4,950